Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
argenx SE ARGX.BR
$370.20
+$1.91 (0.52%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
20506244230.00000000
-
week52high
405.50
-
week52low
267.80
-
Revenue
410746000
-
P/E TTM
-31
-
Beta
0.46183200
-
EPS
-12.21000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 10:59
Описание компании
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Рекомендации
аналитиков
Рекомендации аналитиков
Grading company | New grade | Previous grade | Recommendation date |
---|---|---|---|
Morgan Stanley | Overweight | Equal-Weight | 03 мая 2022 г. |
Morgan Stanley | Equal-Weight | Equal-Weight | 07 мар 2022 г. |
Morgan Stanley | Equal-Weight | Equal-Weight | 01 февр 2022 г. |
Morgan Stanley | Equal-Weight | Equal-Weight | 18 янв 2022 г. |
Morgan Stanley | Overweight | Overweight | 03 авг 2021 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии